Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13(1): 25-32.
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline containing and anthracycline-free chemotherapy regimens in patients with HER2 positive early breast cancer : a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013; 24(9): 2278-84.
Minckwits G, Procter M, Azambuja E, Zardvas D, Benyunes M, Viale G, et al. Adjuvant pertuzumb and trastuzumab in early HER2-positeve breast cancer. N Engl J Med. 2017; 377(7): 702.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019; 380(7): 617-28.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015; 373(21): 2005-14.